Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- GRU's WG Demands Reductions in METI's Budgets for Drug Discovery Research
December 14, 2009
- Korosho Decides How to Respond to GRU's Recommendations
December 14, 2009
- Dutch Industry-Academia Alliances for Bio-Based Innovation Highlighted
December 7, 2009
- Silodosin Recommended for Approval in EU: Kissei
December 7, 2009
- Blue Letter Required for Nexavar
December 7, 2009
- Pfizer, Astellas Launch Caduet Combination Tablets
December 7, 2009
- AnGes Agrees with FDA on SPA for PIII Trial of Collategene
December 7, 2009
- Effectively Use DB for Pharmacovigilance: Dr Chan
December 7, 2009
- Abbott Acquires Global Rights to Biologic Pain Killer from PanGenetics
December 7, 2009
- Otsuka Withdraws Application for Abilify for Major Depression in Europe
December 7, 2009
- Price Maintenance System Essential to Promote Drug Industry: Mr Nagayama
December 7, 2009
- Sanofi-aventis, Regeneron Expand Strategic Antibody Collaboration
December 7, 2009
- Tsumura to File NDA for Daikenchuto in US in 2016
December 7, 2009
- Alfresa Pharma to Expand Contract Manufacturing Business
December 7, 2009
- US GLs Recommend Effient for ACS Patients Following PCI
December 7, 2009
- Pharma Industry to Become a Major Foreign Cashcow: Dr Sakurai of DPJ
December 7, 2009
- Biosimilar of EPO Recommended for Approval
December 7, 2009
- Market Price Survey Finds Mean Yakkasa of 8.4%
December 7, 2009
- Larger Differences in Prices Necessary between Original Drugs and Generics
December 7, 2009
- Japan's 1st GLP-1 Analogue Victoza Recommended for Approval
December 7, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…